The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myerss guibb (Inst); Celcuity (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Eikon (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hanmi Pharm (Inst); HLB Life Science (Inst); ILDONG PHARMACEUTICAL (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Oncology (Inst); Pfizer (Inst); Qurient (Inst); Roche (Inst); Samyang Holdings (Inst); Sanofi (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)
 
Gun Min Kim
No Relationships to Disclose
 
Kyung Hae Jung
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bixink; Celgene; Daiichi Sankyo/Astra Zeneca; Eisai; Eisai; Everest Medicine; Merck; MSD; Novartis; Novartis; Pfizer; Roche; Takeda
 
Hei-Cheul Jeung
No Relationships to Disclose
 
Jieun Lee
No Relationships to Disclose
 
Keun Seok Lee
Consulting or Advisory Role - Bixink; Everest Pharmaceutical; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Dong-A ST (Inst); Novartis (Inst)
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Seok Yun Kang
No Relationships to Disclose
 
Se Hyun Kim
Consulting or Advisory Role - Guardant Health; Yuhan
 
Han Jo Kim
No Relationships to Disclose
 
Kyong Hwa Park
Stock and Other Ownership Interests - iMBDx
Honoraria - Celltrion
Consulting or Advisory Role - AstraZeneca; Daichi Sankyo
Patents, Royalties, Other Intellectual Property - IP transfer fee
Expert Testimony - LegoChem Biosciences
 
Yee Soo Chae
No Relationships to Disclose
 
Su-Jin Koh
No Relationships to Disclose
 
EUN KYUNG CHO
No Relationships to Disclose
 
Keon Uk Park
No Relationships to Disclose
 
Sung Sook Lee
No Relationships to Disclose
 
Ji-Yeon Kim
No Relationships to Disclose
 
In Sil Choi
No Relationships to Disclose
 
Sun Kyung Baek
No Relationships to Disclose
 
Yong Wha Moon
No Relationships to Disclose